We chose these cell lines based on the following rationale: HT-1080 is a NAPRTase-deficient cell line that requires NAMPT for NAD+ production, and DLD-1 is a MutS homolog 6 (MSH6)-lacking carcinoma cell line that can easily develop drug resistance. This evidence concerns the gene MSH6 and carcinoma.